oditrasertib

Oditrasertib (SAR443820, also known as DNL788) is an orally bioavailable, brain-penetrant small molecule inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1). RIPK1 is a critical signaling protein involved in regulating neuroinflammation and cell death. Overactivation of RIPK1 has been implicated in abnormal microglia activity and nerve cell death, contributing to the pathology of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). By inhibiting RIPK1, oditrasertib aims to reduce inflammation and neuronal damage associated with these conditions. The drug was discovered by Denali Therapeutics and is being developed in partnership with Sanofi. It has demonstrated good safety, tolerability, CNS penetration, and robust target engagement in early clinical studies[2][3][5][6].

Other names

oditrasertib